AbstractThe human immunodeficiency virus type-1 (HIV-1) vaccine candidate F4/AS01 has previously been shown to induce potent and persistent polyfunctional CD4+ T-cell responses in HIV-1-seronegative volunteers. This placebo-controlled study evaluated two doses of F4/AS01 1-month apart in antiretroviral treatment (ART)-experienced and ART-naïve HIV-1-infected subjects (1:1 randomisation in each cohort). Safety, HIV-1-specific CD4+ and CD8+ T-cell responses, absolute CD4+ T-cell counts and HIV-1 viral load were monitored for 12 months post-vaccination. Reactogenicity was clinically acceptable and no vaccine-related serious adverse events were reported. The frequency of HIV-1-specific CD4+ T-cells 2 weeks post-dose 2 was significantly higher i...
International audienceVAC-3S is a therapeutic vaccine comprising a highly conserved HIV-gp41 motif c...
An effective therapeutic vaccine that could augment immune control of HIV-1 replication may abrogate...
International audienceIn this placebo-controlled phase II randomized clinical trial, 103 HIV-1 infec...
Background. This phase I/II partially blinded, randomized, dose-ranging study assessed the safety an...
AbstractThe human immunodeficiency virus type-1 (HIV-1) vaccine candidate F4/AS01 has previously bee...
AbstractA recombinant fusion protein (F4) consisting of HIV-1 p17, p24, reverse transcriptase (RT) a...
The impact of the investigational human immunodeficiency virus type 1 (HIV-1) F4/AS01(B) vaccine on ...
INTRODUCTION: Vaccines may be key components of a curative strategy for HIV-1. We investigated wheth...
With the advancement in anti-retroviral therapy (ART) regimens there has been a significant improvem...
BACKGROUND: Combination highly active antiretroviral therapy (HAART) has significantly decreased HIV...
Sequential prime-boost or co-administration of HIV vaccine candidates based on an adjuvanted clade B...
Sequential prime-boost or co-administration of HIV vaccine candidates based on an adjuvanted clade B...
BackgroundPresent combination antiretroviral therapy (cART) alone does not cure HIV infection and re...
With the advancement in anti-retroviral therapy (ART) regimens there has been a significant improvem...
BACKGROUND: Present combination antiretroviral therapy (cART) alone does not cureHIV infection and r...
International audienceVAC-3S is a therapeutic vaccine comprising a highly conserved HIV-gp41 motif c...
An effective therapeutic vaccine that could augment immune control of HIV-1 replication may abrogate...
International audienceIn this placebo-controlled phase II randomized clinical trial, 103 HIV-1 infec...
Background. This phase I/II partially blinded, randomized, dose-ranging study assessed the safety an...
AbstractThe human immunodeficiency virus type-1 (HIV-1) vaccine candidate F4/AS01 has previously bee...
AbstractA recombinant fusion protein (F4) consisting of HIV-1 p17, p24, reverse transcriptase (RT) a...
The impact of the investigational human immunodeficiency virus type 1 (HIV-1) F4/AS01(B) vaccine on ...
INTRODUCTION: Vaccines may be key components of a curative strategy for HIV-1. We investigated wheth...
With the advancement in anti-retroviral therapy (ART) regimens there has been a significant improvem...
BACKGROUND: Combination highly active antiretroviral therapy (HAART) has significantly decreased HIV...
Sequential prime-boost or co-administration of HIV vaccine candidates based on an adjuvanted clade B...
Sequential prime-boost or co-administration of HIV vaccine candidates based on an adjuvanted clade B...
BackgroundPresent combination antiretroviral therapy (cART) alone does not cure HIV infection and re...
With the advancement in anti-retroviral therapy (ART) regimens there has been a significant improvem...
BACKGROUND: Present combination antiretroviral therapy (cART) alone does not cureHIV infection and r...
International audienceVAC-3S is a therapeutic vaccine comprising a highly conserved HIV-gp41 motif c...
An effective therapeutic vaccine that could augment immune control of HIV-1 replication may abrogate...
International audienceIn this placebo-controlled phase II randomized clinical trial, 103 HIV-1 infec...